mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. (Q37680565)
Jump to navigation
Jump to search
scientific article published on 25 October 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. |
scientific article published on 25 October 2013 |
Statements
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1 (English)
Rakesh K Jain
David P Kodack
Anthony C Faber
Erin M Coffee
Carlotta Costa
Anahita Dastur
Alan T Yeo
Elena J Edelman
Ah Ting Tam
Jessica L Boisvert
Randy J Milano
Jatin Roper
Ryan B Corcoran
Miguel N Rivera
Sridhar Ramaswamy
Kenneth E Hung
Cyril H Benes
Jeffrey A Engelman
25 October 2013
1 reference